Up to 80% of patients experience prolonged illness after COVID-19, characterized by prolonged malaise, headaches, generalized fatigue, sleep difficulties, hair loss, smell disorder, decreased appetite, painful joints, dyspnea, chest pain and cognitive dysfunction. Long COVID may persist for months after acute infection, and it is likely that patients who did not receive adequate treatment during the symptomatic phase are much more likely to develop long COVID. Treatment should be individualized to clinical signs and symptoms. (this section is borrowed from the FLCCC Website, coivdcriticalcare.com)
Long Haul COVID Syndrome (LHCS)—commonly known as long COVID—is characterized by prolonged malaise, headaches, generalized fatigue, sleep difficulties, hair loss, smell disorder, decreased appetite, painful joints, dyspnea, chest pain and cognitive dysfunction.
Up to 80% of patients experience prolonged illness after COVID-19. Long COVID is not only seen after COVID infection but is also being observed in some people who have received vaccines (likely due to monocyte/microglia activation by the spike protein from the vaccine). Long COVID may persist for months after the acute infection and almost half of patients report reduced quality of life.
Patients may suffer prolonged neuropsychological symptoms, including multiple domains of cognition. A puzzling feature of long COVID is that it is not predicted by initial disease severity; it frequently affects mild-to-moderate cases and younger adults who did not require respiratory support or intensive care.
The symptom set of long COVID is, in the majority of cases, very similar to chronic inflammatory response syndrome (CIRS)/myalgic encephalomyelitis/chronic fatigue syndrome. An important differentiating factor from CIRS is the observation that long COVID continues to improve on its own, albeit slowly in the majority of cases.
Another important observation is that long COVID includes more young people compared to severe COVID, which affects older people or persons with co-morbidities.
Long COVID is highly heterogeneous and likely results from a variety of pathogenetic mechanisms. Furthermore, it is likely that delayed treatment (with ivermectin, etc.) in the early symptomatic phase results in a high viral load (high spike protein load), which increases the risk and severity of long COVID.
Major public health authorities do not recognize post-COVID-vaccine injuries no specific ICD classification code exists for this disease. However, while no official definition exists, a temporal correlation between receiving a COVID-19 vaccine and the beginning or worsening of a patient’s clinical manifestations is sufficient to diagnose a COVID-19 vaccine-induced injury, when symptoms are otherwise unexplained by concurrent causes.
Since there are no published reports detailing how to manage vaccine-injured patients, our treatment approach is based on the postulated pathogenetic mechanism, clinical observation, and patient anecdotes. Treatment must be individualized according to each patient’s presenting symptoms and disease syndromes. Chances are, not all patients will respond equally to the same intervention; a particular intervention may be life-saving for one patient and completely ineffective for another.
Early treatment is essential; the response to treatment will most likely be attenuated when treatment is delayed. (this section is borrowed from the FLCCC Website, coivdcriticalcare.com)